Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 40 or older, male or female~* 6-mo. history of walking limitation or symptoms of intermittent claudication (IC) in at least 1 lower limb, severity of which has not changed in the past 3 mo. and diagnosed by principal investigator as clinically stable Fontaine Stage II peripheral artery disease (PAD)~* Diagnosis of PAD secondary to atherosclerosis~* If ankle-brachial index (ABI) is \> 1.3 or cannot be measured in either leg, vascular etiology documented by toe-brachial index (TBI) ≤ 0.7 in at least 1 leg~* Claudication severity, meds. for the treatment of coronary artery disease (CAD), PAD and IC, and exercise habits should be clinically stable for 3 mo. prior to Screening (SCRN) and during study. Pt. is not likely to change smoking and/or exercise habits during study~* On an exercise treadmill test (ETT), peak walking time (PWT) of at least 1 min., but no more than 12 min. at Baseline~* Willing and able to discontinue Pletal or Trental for 21 days before SCRN and during study~* Antihypertensive therapy, cholesterol-lowering therapy, chronic oral nitrates, and diabetic therapy have been stable for 30 days prior to SCRN~* Willing and able to provide written, signed, informed consent after the nature of the study has been explained and prior to any research-related procedures~* Willing and able to comply with all study-related procedures~* Sexually active patients must use an acceptable method of contraception while participating in the study~* Females of childbearing potential must have a negative pregnancy test at SCRN and have additional pregnancy tests during the study~Exclusion Criteria:~* Pregnant or lactating~* Current or history of critical limb ischemia (CLI)~* Pts. in whom artery insufficiency in the lower extremity is the result of acute limb ischemia (ALI) or an immunological or inflammatory non-atherosclerotic disorder~* Pts. in whom walking impairment due to pain is the result of other non-atherosclerotic co-morbid conditions~* A surgical intervention to alleviate symptoms of IC or PAD-specific endovascular intervention or cardiovascular surgery within 3 mo. of SCRN~* Walking limited by reasons other than claudication~* Conditions other than IC of significant severity that could confound PWT on the ETT~* Concurrent severe congestive heart failure (CHF)~* Life-threatening ventricular arrhythmias, unstable angina, and/or myocardial infarction (MI) within 3 mo. before enrollment (ENRL)~* Coronary artery bypass grafting or percutaneous coronary intervention within 4 mo. before ENRL~* Renal and/or carotid revascularization procedure within 3 mo. of ENRL~* Transient ischemic attack (TIA) within 3 mo. before ENRL~* Deep vein thrombosis (DVT) within 3 mo. before ENRL~* Severe chronic obstructive pulmonary disease (COPD)~* Thrombocytopenia~* Undergoing hemodialysis or peritoneal dialysis~* Pts. w/immunocompromised conditions, organ transplant recipients and/or need for immunosuppressive therapy~* Neurological dementia~* Stroke~* Clinically significant electrocardiogram (ECG) change during or after ETT at SCRN or Baseline visit(s)~* Cerebrovascular infarct within 3 mo. of SCRN~* Poorly controlled type 1 or type 2 diabetes at SCRN~* History of migraine headaches within last 12 mo.~* Patients with clinically significant abnormal hematology labs or blood chemistry labs~* Body mass index \> 35~* Hypertension at SCRN defined as resting BP values of \> 170 mmHg systolic and/or \> 110 mmHg diastolic~* Hypotension at SCRN defined as resting BP values \< 100 mmHg systolic or \< 55 mmHg diastolic or symptomatic hypotension~* Previous treatment with any formulation of TSC~* Known allergy or hypersensitivity to any excipient (gamma-cyclodextrin, mannitol, glycine) of TSC formulation~* Previous treatment with gene therapy or other VEGF-related treatment within 12 mo. of SCRN~* Patients with recent history of alcoholism or drug abuse, or severe emotional, behavioral, or psychiatric problems~* Patients receiving experimental medications or participating in other study using an experimental drug or procedure within 45 days prior to ENRL

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): .25 mg/kg TSC
- 2 (Type: EXPERIMENTAL): .5 mg/kg TSC
- 3 (Type: EXPERIMENTAL): .75 mg/kg TSC
- 4 (Type: EXPERIMENTAL): 1.0 mg/kg TSC
- 5 (Type: EXPERIMENTAL): 1.25 mg/kg TSC
- 6 (Type: EXPERIMENTAL): 1.5 mg/kg TSC
- 7 (Type: EXPERIMENTAL): 1.75 mg/kg TSC
- 8 (Type: EXPERIMENTAL): 2.0 mg/kg TSC
- 9 (Type: PLACEBO_COMPARATOR): 5.0 mL 0.9% normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).